Combined Therapies for DMD, page-94

There wasn't really anything much in new data.

I like that Woodcock presented it as a clinician made it clear at the start that he was the principal investigator of the trial but had no direct interest in the company. Primary endpoint was on the safety which no serious adverse events - quite a few but none of them serious mostly skin. All patients have completed dosing with final data early 2020 following completion of safety monitoring period. Secondary endpoints interesting, possibly encouraging but can't really say any more than that given the trial is open without a control.

Interesting, encouraging, warrants further investigation - they were probably the take home words I noted. Again that just runs with the plan to move forward to a IIb but it also shows why it needs a control to be able to deliver convincing data.